NEWS

Catalyst OrthoScience initiates a controlled, limited user release of the planning software to test the software in clinical settings NAPLES, Fla., March 21, 2022 – Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced that the platform technology for its Archer™ 3D…

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has named Carl O’Connell as president and chief executive officer effective immediately. O’Connell replaces Brian Hutchison, who is stepping down. Hutchison joined the company as executive chairman and interim CEO in June 2018 before being asked…

"Despite an up-and-down year, Catalyst Orthoscience appears poised for takeoff in the new year. One big aid? It has a product surgeons and patients alike love." View Article, Dec 20, 2021

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.